Kojin Therapeutics Information

Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and cardiovascular, immunologic, and degenerative diseases. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis. The Kojin founding team brings together leadership in chemical biology, genetics, immunology, cancer therapeutics, and drug discovery and development, and includes: Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan.